Piper Jaffray Keeps Biogen at Market Perform

Analyst Mark E. Karvosky says despite the third case of PML in one of its Tysabri patients, he would still buy the pharma's stock under $36

Piper Jaffray keeps Biogen Idec (BIIB ) at market perform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.